Compare Tango Therapeutics Inc. (TNGX) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs State Street Technology Select Sector SPDR ETF — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while State Street Technology Select Sector SPDR ETF trades at $188.84 (market cap $129.38B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 34.5× Tango Therapeutics Inc.'s market cap, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| TNGX | XLK | |
|---|---|---|
Market Cap | $3.75B | $129.38B |
Volume | 9,619,106 | 6,753,008 |
Sector | Health | Sector/Thematic |
52-Week High | $32.90 | $202.00 |
52-Week Low | $7.50 | $127.49 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
XLK trades at $196.24, down slightly by 0.06% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF faces concentration concerns despite its tech sector exposure, with recent news highlighting AI-driven opportunities and potential interest rate impacts. Support levels are established at $195 and $194, with resistance at $198 and $199.
The outlook for XLK remains positive given strong AI investment themes and large-cap tech resilience, though risks include Fed rate hike sensitivity and sector concentration. Investor sentiment is mixed, balancing growth potential against macroeconomic headwinds and valuation pressures in the technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
